| Literature DB >> 29963586 |
Abstract
Pain is a significant problem in older adults with cancer as older adults often receive suboptimal pain management. While overmedication can lead to adverse effects, under management of pain can lead to physiological and psychological problems such as functional decline and depression. This manuscript will discuss the assessment and management of pain in older adults, in consideration of the pharmacodynamic changes related to aging and other individual considerations. Current evidence from filtered and unfiltered sources, PubMed, current guidelines. Unrelieved pain can have a detrimental impact on older adults. A team approach is essential to assess patients at each encounter, consider the social environment in which the patient resides, and employ pharmacologic and nonpharmacologic strategies that are evidence-based and are tailored to the specific cancer pain syndrome.Entities:
Keywords: Cancer; elderly; geriatrics; older adults; pain; pharmacodynamics; pharmacokinetics
Year: 2018 PMID: 29963586 PMCID: PMC5996586 DOI: 10.4103/apjon.apjon_11_18
Source DB: PubMed Journal: Asia Pac J Oncol Nurs ISSN: 2347-5625
The 5-step approach to pain assessment
| Step | Pain Assessment |
|---|---|
| 1. Self-report | • Attempt to obtain a self-report of pain from the patient Use a 0-10 scale if able |
| 2. Pathology | • Consider the patient’s physiological condition (s) |
| 3. Behaviors | • Assess for any patient behaviors that may indicate the presence of pain |
| 4. Caregiver Input | • Ask the caregiver about their perceptions of their loved one’s pain |
| 5. Analgesic Trial | • Assume pain present |
Physiologic changes with aging
| Pharmacodynamic property | Physiologic change | Consequences | Pharmacologic implications |
|---|---|---|---|
| Absorption | Reduced gastric and intestinal motility | Prolonged colon transit times | Decreased and inadequate absorption of drugs |
| Distribution | Increased ratio of fat to lean body mass | Increased fat and reduced water leads to an increased distribution of lipophilic agents | Delayed onset of effect and a delayed rate of elimination of lipophilic agents such as fentanyl leading to toxicity |
| Hepatic | Function is reduced with age Reduction in the amount of cytochrome P450 (CYP450) enzymes | Effects on aging pathways unclear Probable alteration in metabolism as P450 metabolizes 40%-50% of all medications | Potential for prolonged drug half-lives, leading to extended periods of drug circulation, uptake, and distribution Potential for adverse effects from drug-drug interactions when patients are co-administered medications processed by the CYP450 enzyme system |
| Renal | Reduction in mass and blood flow | Lower renal clearance and glomerular filtration rate (<60 mL/min) | Potential for the accumulation metabolites in drugs eliminated primarily by the kidney leading to increased toxicity |
Opioid considerations in older adults
| Opioid | Older adult considerations |
|---|---|
| Morphine | Potential for accumulation of M3G and M6G in patients with renal compromise |
| Oxycodone | Metabolism mediated by the CYP450 enzyme, but clinical implications are unclear |
| Hydromorphone | Two active metabolites exist, H3G and H6G, although the impact of these metabolites is unclear |
| Fentanyl | Highly lipophilic and onset dependent on route of administration |
| Methadone | Highly protein bound resulting in an extended half-life which can lead to drug accumulation and oversedation QTc prolongation, especially in higher doses >100 mg/day |
M3G: Morphine-3-glucuronide, M6G: Morphine-6-glucuronide, H3G: Hydromorphone-3-glucuronide, H6G: Hydromorphone-6-glucuronide